Table 4.
IC50 (µm) valuesa of the ligands HTSC1–5, palladium(II) complexes [Pd(TSC1–5)2], and cisplatin against the different human tumor cell linesb.
| Human tumor cell lines | H460 | DU145 | MCF-7 | M14 | HT-29 | K562 |
|---|---|---|---|---|---|---|
| HTSC1 | >250 | >250 | >250 | >250 | >250 | 70.86 |
| HTSC2 | >250 | 31.55 | 38.05 | >250 | >250 | 32.89 |
| HTSC3 | 23.48 | 26.64 | 34.00 | 28.67 | 25.73 | 35.05 |
| HTSC4 | 39.65 | 26.45 | 29.94 | >250 | >250 | 24.66 |
| HTSC5 | 24.95 | 31.60 | 25.46 | 27.31 | 26.72 | 27.76 |
| [Pd(TSC1)2] | 9.40 | 8.27 | 6.95 | 9.87 | 8.20 | 9.43 |
| [Pd(TSC2)2] | 2.26 | 2.05 | 1.61 | 2.14 | 1.87 | 1.95 |
| [Pd(TSC3)2] | 0.23 | 0.01 | 0.13 | 0.05 | 0.05 | 0.02 |
| [Pd(TSC4)2] | 2.05 | 2.39 | 2.14 | 2.27 | 2.37 | 1.84 |
| [Pd(TSC5)2] | 0.68 | 0.84 | 0.78 | 1.06 | 1.04 | 0.65 |
| cisplatin | 2.85 | 6.50 | 7.20 | 2.95 | 7.60 | 3.20 |
aIC50 corresponds to the concentration required to inhibit 50% of the cell growth when the cells are exposed to the compounds during 48 h. Each value is the average of two independent experiments.
bLung large cell carcinoma (H460), prostate carcinoma (DU145), breast adenocarcinoma (MCF-7), amelanotic melanoma (M-14), colon adenocarcinoma (HT-29), and chronic myelogenous leukemia (K562).